Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Cognitive & neurological research

DSIP (Delta Sleep-Inducing Peptide): Research Overview

Naturally occurring peptide studied in sleep and stress research since the 1970s.

Also known as Delta Sleep-Inducing Peptide

Research use onlyStrongest evidence: controlled clinical trialReviewed
DatabaseReferences

What is DSIP?

DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.

What is DSIP researched for?

  • Promotes delta wave sleep, the most restorative sleep phase for physical recovery.
  • Reduces sleep latency and nocturnal awakenings without morning grogginess.
  • Supports natural sleep cycles rather than forcing sedation like traditional sleep aids.
  • Helps regulate cortisol and stress response through HPA axis modulation.
  • Supports emotional balance without sedation.
  • May help reduce anxiety through neuromodulatory effects.
  • Significantly reduced pain levels in 6 of 7 patients with chronic pain conditions.
  • Helps manage withdrawal symptoms in alcohol and opioid-dependent patients.
  • Supports post-training recovery through enhanced sleep quality.
  • One clinical study found 6 of 7 chronic pain patients experienced significant pain reduction with IV DSIP (25 nmol for 10 days). It works through multiple pathways including endogenous opioid modulation and stress reduction. However, human data is limited primarily to small studies, so pain management requires medical oversight.

How does DSIP work?

Modulates multiple neurotransmitter systems including GABA enhancement, NMDA receptor interaction, and endogenous opioid system modulation. Also regulates hypothalamic-pituitary-adrenal axis for stress response.

Reported targets: NMDA receptor

References

  1. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study

    Bes F, Hofman W, Schuur J, et al. · Neuropsychobiology · 1992

    Double-blind placebo-controlled study; DSIP (15-30 nmol for 6 consecutive nights) showed higher sleep efficiency and shorter sleep latency, though statistical effects were weak.

    Controlled clinical trial · PMID 1299794

  2. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study

    Larbig W, Gerber WD, Kluck M, et al. · European neurology · 1984

    7 patients with chronic pain (migraine, vasomotor headaches); 25 nmol IV DSIP for 10 days significantly reduced pain levels in 6 of 7 patients.

    Early human study · PMID 6548970

  3. DSIP in the treatment of withdrawal syndromes from alcohol and opiates

    Dick P, Costa C, Fayolle K, et al. · European neurology · 1984

    107 patients (47 alcohol, 60 opiate withdrawal); DSIP (25 nmol/kg IV) produced beneficial effects in 97% of opiate addicts and 87% of alcoholics with immediate onset and lasting symptom relief.

    Controlled clinical trial · PMID 6548969

  4. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior

    Schneider-Helmert D, Gnirss F, Monnier M, et al. · International journal of clinical pharmacology, therapy, and toxicology · 1981

    6 normal volunteers; 25 nmol/kg IV DSIP induced 59% increase in total sleep time within 130 minutes; improved subsequent night sleep efficiency without sedation.

    PMID 6895513

  5. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke

    Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. · Molecules (Basel, Switzerland) · 2021

    120 mcg/kg intranasal DSIP for 8 days accelerated motor function recovery (rotarod test) after focal stroke in rats; brain infarction was smaller but not statistically significant.

    Animal study · PMID 34500605

  6. Successful Treatment of Withdrawal Symptoms with Delta Sleep-Inducing Peptide Larbig W, Gerber WD, Kluck M, Schoenenberger GA Neuropsychobiology

    1984

    DSIP (25 nmol/kg IV) administered to 67 patients; beneficial effect in 48 of 49 evaluable patients (22 alcoholics and 26 of 27 opiate addicts) with good tolerance.

  7. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors

    Dick P, Grandjean ME, Tissot R · Neuropsychobiology · 1983

    PMID 6328354

Common questions

Will DSIP cause dependence or tolerance like sleeping pills?

No dependence or tolerance has been reported with DSIP in clinical studies, unlike traditional sedatives. Its naturally occurring structure and neuromodulatory mechanism (GABA enhancement, HPA axis modulation) work through physiological pathways rather than receptor desensitization, making it suitable for short cycles without habituation concerns.

Is DSIP useful for managing withdrawal from alcohol or opioids?

Yes, research shows DSIP is remarkably effective for withdrawal management—87% of alcoholics and 97% of opioid addicts showed beneficial effects in clinical trials using IV administration (25 nmol/kg). It reduces withdrawal symptoms through immediate onset and HPA axis normalization, making it relevant for addiction medicine.